Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q1 2023 · 10-Q
Revenue$1.83M$1.83M+7.8% vs Q1 2022 Net Income-$142.73M-$142.73MN/M vs Q1 2022 EPS Diluted-$0.92-$0.92N/M vs Q1 2022 Operating Income-$126,163,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
Free Cash Flowderived-$144,334,000N/M Margins · derivedOperating margin-6909.3%+3343.3 pt vs Q1 2022
Net margin-7816.6%+4068.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end